<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical use of topical anesthetics in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical use of topical anesthetics in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical use of topical anesthetics in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah C Hsu, MD, MEd</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne M Stack, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Wiley, II, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The use of topical anesthetics for pain management during minor procedures in children is reviewed here.</p><p>A general approach to the management of pain and sedation in children, and prevention and treatment of neonatal pain are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6254.html" rel="external">"Pain in children: Approach to pain assessment and overview of management principles"</a> and  <a class="medical medical_review" href="/d/html/5018.html" rel="external">"Management and prevention of pain in neonates"</a>.)</p><p class="headingAnchor" id="H217021048"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Local anesthetics work by reversibly blocking sodium channels within the nerve fibers, which prevents transmission of pain signals by disrupting depolarization of the nerve (see  <a class="medical medical_review" href="/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics", section on 'Anatomy and physiology'</a>). In the skin, these nerve fibers are located in the dermis and epidermis and are covered by the water impermeable stratum corneum. Topical anesthetics overcome this barrier by either passive diffusion from creams or gels or the use of needle-free methods such as pressured gas drug delivery, heat-enhanced diffusion, or iontophoresis [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H486598070"><span class="h1">SELECTION OF A TOPICAL AGENT</span></p><p class="headingAnchor" id="H2949654013"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Painful procedures, such as venipuncture, intravenous (IV) cannulation, intramuscular (IM) injection, laceration repair, and lumbar puncture (LP) are common in pediatrics and cause distress to children and their caretakers. The stress response to pain is associated with metabolic and hormonal changes that are attenuated by local anesthetics [<a href="#rid2">2,3</a>].</p><p>Local anesthetics can be injected; however, topical analgesics, either topical anesthetics or vapocoolant spray can be applied without needles and can reduce the need for physical and chemical restraints [<a href="#rid4">4</a>]. These agents also avoid the tissue distortion that occurs with infiltrated anesthetics [<a href="#rid5">5</a>]. As discussed below, the selection of the topical anesthetic primarily depends upon the type and urgency of the procedure, the provider's knowledge and comfort with different types of application procedures, and patient preference  (<a class="graphic graphic_table graphicRef50950" href="/d/graphic/50950.html" rel="external">table 1</a>).</p><p>In many children undergoing minimally painful procedures, local anesthetics can be delivered topically to diminish or abolish the pain without the need for sedation, especially when age-appropriate nonpharmacologic interventions are used. When nonpharmacologic interventions and topical anesthetics are <strong>not</strong> sufficient and minimal sedation is necessary, inhaled <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> or intranasal <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> are suggested. (See  <a class="medical medical_review" href="/d/html/85542.html" rel="external">"Procedural sedation in children: Selection of medications", section on 'Minimally painful procedures'</a>.)</p><p class="headingAnchor" id="H1750773061"><span class="h2">Preparation</span><span class="headingEndMark"> — </span>Prior to minor painful procedures, nonpharmacologic interventions (eg, behavioral or cognitive techniques) are also essential to attenuate pain in the conscious child and enhance the benefit of local analgesia. A table provides suggested techniques and the appropriate timing of their use prior and during the procedure  (<a class="graphic graphic_table graphicRef50950" href="/d/graphic/50950.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/6330.html" rel="external">"Procedural sedation in children: Approach", section on 'Nonpharmacologic interventions'</a>.)</p><p>Immediate-type allergy (including anaphylaxis) to local anesthetics is rare. However local anesthetics can cause contact dermatitis. Avoid topical use in patients with a history of blistering skin lesions or localized eczema after past application. (See  <a class="medical medical_review" href="/d/html/2084.html" rel="external">"Allergic reactions to local anesthetics"</a>.)</p><p>Although toxicity is rare and typically associated with excessive application, providers should understand the signs and symptoms of local anesthetic toxicity (eg, seizures and cardiotoxicity) and know the appropriate management. The table provides a rapid overview of this information  (<a class="graphic graphic_table graphicRef107887" href="/d/graphic/107887.html" rel="external">table 2</a>). </p><p>Selected agents (eg, <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="10228" href="/d/drug information/10228.html" rel="external">prilocaine</a>, and <a class="drug drug_pediatric" data-topicid="13008" href="/d/drug information/13008.html" rel="external">benzocaine</a>) also have the potential to cause methemoglobinemia, especially in infants younger than 12 months of age with predisposition to methemoglobinemia (eg, G6PD deficiency or taking methemoglobin-inducing medication), and the provider should be aware of clinical features and treatment of methemoglobinemia as discussed separately. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia"</a>.)</p><p class="headingAnchor" id="H3618544452"><span class="h2">Vascular access or venipuncture</span><span class="headingEndMark"> — </span>The approach to topical analgesia for vascular access or venipuncture varies for nonurgent or urgent procedures:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonurgent</strong> – Whenever available, children should be offered some form of topical analgesia prior to nonurgent venipuncture, IV catheter placement, or percutaneous access of an indwelling central line. We suggest liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> gel, <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> cream, a heated lidocaine and tetracaine patch, or needle-free lidocaine administration (eg, J-tip) rather than vapocoolant spray or lidocaine iontophoresis to minimize the pain of venipuncture or vascular access. Needle-free lidocaine administration reduces pain within 1 to 3 minutes of use. For topical agents, minimum application time is 20 to 30 minutes for a heated lidocaine and tetracaine patch, 30 minutes for liposomal lidocaine, 30 to 45 minutes for tetracaine gel, and 60 minutes for lidocaine-prilocaine. The efficacy of all of these agents is roughly equivalent  (<a class="graphic graphic_table graphicRef117407" href="/d/graphic/117407.html" rel="external">table 3</a>). The longer application time for lidocaine-prilocaine may practically limit its usefulness relative to the other preparations. Nonpharmacologic approaches are an essential part of optimizing the analgesia for all of these agents  (<a class="graphic graphic_table graphicRef50950" href="/d/graphic/50950.html" rel="external">table 1</a>). Needle-free lidocaine delivery is also appropriate to provide analgesia prior to urgent percutaneous vascular access as discussed below. </p><p></p><p class="bulletIndent1">By contrast, the efficacy of vapocoolant agents is highly dependent upon spraying time [<a href="#rid6">6-8</a>]. Vapocoolant spray application is also uncomfortable, and the duration of analgesia is short and may be inadequate for prolonged attempts at IV access. <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">Lidocaine</a> iontophoresis also provides effective pain relief for venous catheter placement or venipuncture within 10 to 20 minutes [<a href="#rid9">9-12</a>]. However, the discomfort associated with the procedure, the demand on provider time relative to other techniques, significant local skin reactions (including burns), and the emergence of liposomal lidocaine as a nonpainful technique that has an onset of action similar to iontophoresis has limited the use of this technique in clinical practice.</p><p></p><p class="bulletIndent1">Multiple studies have demonstrated that <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> reduces pain associated with procedures such as venous or arterial puncture, placement of IV catheters; access to subcutaneous drug reservoirs, immunization, LP, and laceration repair [<a href="#rid1">1,13,14</a>]. As an example, in a randomized trial in 258 children, subjective pain scores in response to venipuncture and venous cannulation were significantly lower with lidocaine-prilocaine than with placebo [<a href="#rid15">15</a>]. Another randomized trial evaluated the effect of lidocaine-prilocaine on distress and ease of procedure in children undergoing phlebotomy in an office practice [<a href="#rid16">16</a>]. Measures of distress and ease of procedure improved significantly among children who had lidocaine-prilocaine. </p><p></p><p class="bulletIndent1">Studies that have compared <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> to other topical anesthetic formulations, such as liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> gel, or a heated lidocaine and tetracaine patch show that these alternative formulations have equivalent to better pain relief with a shorter onset of action [<a href="#rid1">1,17-24</a>]. First attempt success rate is similar among the cream or gel preparations but is better for the heated patch. As an example, in a multicenter trial of children undergoing IV placement, providers using a heated lidocaine and tetracaine patch had a higher first attempt success rate than those using lidocaine-prilocaine cream (92 versus 85 percent, respectively) [<a href="#rid24">24</a>]. The per-application cost of the gel and cream preparations are similar while the cost of the heated patch is higher.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent</strong> – We suggest that awake patients, who are undergoing urgent venipuncture, IV catheter placement or percutaneous access of an indwelling central line, receive analgesia by needle-free <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> delivery or local infiltration of 1% buffered lidocaine solution via a 30-gauge needle rather than administration of vapocoolant spray. Nonpharmacologic techniques appropriate to an urgent procedure should also be used  (<a class="graphic graphic_table graphicRef50950" href="/d/graphic/50950.html" rel="external">table 1</a>). (See <a class="local">'Needle-free lidocaine delivery'</a> below and <a class="local">'Vapocoolant spray'</a> below and  <a class="medical medical_review" href="/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics", section on 'Lidocaine'</a>.)</p><p></p><p class="bulletIndent1">In stable patients and when equipment and properly trained personnel are available, local analgesia may be augmented by inhalation of <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> which provides rapid mild to moderate sedation. (See  <a class="medical medical_review" href="/d/html/82857.html" rel="external">"Pediatric procedural sedation: Pharmacologic agents", section on 'Nitrous oxide'</a>.)</p><p></p><p class="bulletIndent1">Randomized controlled trials have shown that use of a carbon dioxide propelled needle-free <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> delivery reduces the pain of venipuncture or IV insertion within a few minutes of use when compared with placebo and may provide better anesthetic effect than prilocaine-lidocaine, or liposomal lidocaine [<a href="#rid25">25-29</a>]. Although these studies support a rapid reduction of pain by needle-free lidocaine delivery devices relative to placebo, <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a>, or liposomal lidocaine, the degree of pain relief varies, and the clinical utility of needle-free lidocaine delivery is uncertain for nonemergent procedures. However, the ability to provide analgesia within 1 to 3 minutes of use may make this device helpful for patients undergoing urgent venipuncture or vascular access procedures.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">Lidocaine</a> injection and vapocoolant spray are the primary alternatives to needle-free lidocaine delivery when the procedure needs to be accomplished urgently. Onset of action occurs rapidly and analgesia is excellent for injected lidocaine. The pain of injection can be mitigated by using a buffered 1% lidocaine solution and a 30-gauge needle [<a href="#rid1">1</a>]. (See <a class="local">'Vapocoolant spray'</a> below and  <a class="medical medical_review" href="/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics", section on 'Lidocaine'</a>.)</p><p></p><p class="bulletIndent1">Vapocoolant sprays are uncomfortable to the patient and, due to the brief duration of effect, may require two providers to administer. Analgesia may wear off before the procedure is successfully completed. For all of these reasons, it is an inferior approach to pain control during urgent procedures. (See <a class="local">'Vapocoolant spray'</a> below.)</p><p></p><p class="headingAnchor" id="H3078849893"><span class="h3">Standing orders</span><span class="headingEndMark"> — </span>In certain jurisdictions, emergency department (ED) standing orders or triage protocols for <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a>, liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, or <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> gel application in triage permit nurses to place topical anesthetics on children likely to undergo dermal procedures and are utilized in many hospitals  (<a class="graphic graphic_algorithm graphicRef67047" href="/d/graphic/67047.html" rel="external">algorithm 1</a>) [<a href="#rid30">30,31</a>]. Standing orders help encourage the use of topical anesthetics and are an important part of implementing a systemic approach to pain management for pediatric venous access in the ED or other hospital unit [<a href="#rid32">32</a>]. Nonpharmacologic approaches should also be used to maximize the benefit of topical anesthetics for pain relief  (<a class="graphic graphic_table graphicRef50950" href="/d/graphic/50950.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2576160844"><span class="h2">Intramuscular injections</span><span class="headingEndMark"> — </span>For infants and children undergoing IM injections, we suggest analgesia with topical anesthetics (prilocaine-lidocaine, liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, or <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> gel) prior to injections instead of vapocoolant spray or other cooling methods (eg, application of an ice pack). In a network meta-analysis of eight placebo-controlled trials performed in infants and children undergoing IM injections, <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> had a high probability of providing the best pain control when compared with vapocoolant spray or, in neonates and young infants, oral <a class="drug drug_pediatric" data-topicid="16103" href="/d/drug information/16103.html" rel="external">sucrose</a> [<a href="#rid33">33</a>]. </p><p>Given that studies of other procedures suggest equivalent analgesia among the topical anesthetics, these results suggest that topical anesthetics either alone or, in combination with oral <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> or <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a> in older infants and children or, in young infants, oral <a class="drug drug_pediatric" data-topicid="16103" href="/d/drug information/16103.html" rel="external">sucrose</a> may reduce the pain of IM injection to a greater extent than cooling methods. (See <a class="local">'Lidocaine-prilocaine'</a> below and <a class="local">'Liposomal lidocaine'</a> below and <a class="local">'Tetracaine gel'</a> below.)</p><p class="headingAnchor" id="H768202792"><span class="h2">Other procedures through intact skin</span><span class="headingEndMark"> — </span>Topical anesthetics may also be used on intact skin for pain management during other procedures such as joint aspiration, paraphimosis reduction, zipper injuries, elective LP, and curettage of molluscum contagiosum as discussed separately: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6425.html" rel="external">"Joint aspiration or injection in children: Indications, technique, and complications", section on 'Anesthesia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6482.html" rel="external">"Paraphimosis: Clinical manifestations, diagnosis, and treatment", section on 'Pain control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6326.html" rel="external">"Management of zipper entrapment injuries", section on 'Local anesthesia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6325.html" rel="external">"Lumbar puncture in children", section on 'Procedure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4033.html" rel="external">"Molluscum contagiosum", section on 'Curettage'</a>.)</p><p></p><p class="headingAnchor" id="H641311331"><span class="h2">Laceration repair</span><span class="headingEndMark"> — </span>For uncomplicated facial or scalp lacerations &lt;5 cm in length, we suggest initial pain control with topical LET (lidocaine-epinephrine-tetracaine) rather than injected local anesthetic. In addition, LET may reduce the pain of local infiltration of anesthetics for lacerations on other parts of the body with the exception of sites near mucus membranes, poorly vascularized sites (eg, auricle), or genitalia where placement of LET is contraindicated. However, it does not typically provide complete analgesia [<a href="#rid34">34</a>]. LET is available in an aqueous solution and a <a class="drug drug_pediatric" data-topicid="135074" href="/d/drug information/135074.html" rel="external">methylcellulose</a> based gel. The gel is preferred because it maintains better contact with the open wound and is easier to apply. (See <a class="local">'Lidocaine-epinephrine-tetracaine (LET)'</a> below.)</p><p>A maximum of 3 mL of LET gel or solution should be applied for at least 20 minutes prior to laceration repair. Irrigation of the wound and removal of debris and blood clots before application maximizes penetration of the anesthetic although it is not necessary for most simple lacerations [<a href="#rid35">35</a>]. LET dosing, application, and adverse effects are discussed in greater detail below. (See <a class="local">'Lidocaine-epinephrine-tetracaine (LET)'</a> below.)</p><p>LET should <strong>not</strong> be applied to mucosal surfaces or in areas that have an end arterial supply, such as the tips of digits, penis, nose, and ears [<a href="#rid17">17,34</a>]. LET is <strong>not</strong> recommended for large wounds (&gt;5 cm in length) or multiple lacerations with a total length of &gt;5 cm because the amount required for adequate anesthesia might exceed the recommended dose and risk toxicity [<a href="#rid17">17,34,36</a>].</p><p>LET is the topical anesthetic most frequently used for laceration repair. Based upon several trials, it provides adequate local anesthesia for wound closure in 75 to 90 percent of scalp and facial lacerations [<a href="#rid34">34,36-38</a>]. If anesthesia is inadequate with LET alone, supplemental 1% <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> solution without <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> and, buffered, when available, is injected through the wound edges for suturing. LET also reduces the pain of lidocaine injection [<a href="#rid39">39,40</a>]. (See <a class="local">'Lidocaine-epinephrine-tetracaine (LET)'</a> below and  <a class="medical medical_review" href="/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics", section on 'Lidocaine'</a>.)</p><p>Depending upon the patient and the specific type of wound closure, mild or deeper sedation may also be required for optimal laceration closure. (See  <a class="medical medical_review" href="/d/html/85542.html" rel="external">"Procedural sedation in children: Selection of medications", section on 'Approach'</a>.)</p><p class="headingAnchor" id="H1933248682"><span class="h3">Standing orders</span><span class="headingEndMark"> — </span>In order to expedite care and where permitted, many hospital EDs have standing orders or triage protocols for application of LET to lacerations in triage [<a href="#rid30">30</a>]. When implementing standing orders, we suggest the following criteria [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Eligible patients – Simple lacerations &lt;5 cm in length (age &gt;3 months and weight &gt;5 kg)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contraindications</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lacerations of mucous membranes (eg, lip, vulva) or regions where it may cause vascular compromise (eg, digits, penis, ear, nose)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Grossly contaminated wounds</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with allergy to amide or ester local anesthetics</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Procedure</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Place 3 mL of LET mixed with cellulose on the open wound (preferred) OR apply LET solution into the wound as described separately (see <a class="local">'Lidocaine-epinephrine-tetracaine (LET)'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cover with an occlusive dressing (eg, gauze with tape or adhesive polyurethane film dressing [eg, Tegaderm or Opsite]) for at least 30 minutes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Document the time of placement in the patient's medical record</p><p></p><p class="headingAnchor" id="H1651018532"><span class="h2">Mucosal surfaces</span><span class="headingEndMark"> — </span>When properly used, topical anesthetic mucosal preparations (eg, <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a>, <a class="drug drug_pediatric" data-topicid="13008" href="/d/drug information/13008.html" rel="external">benzocaine</a>, xylocaine, and amethocaine) have been shown to decrease the pain of intraoral dental injections [<a href="#rid41">41-43</a>]. Lidocaine preparations are equivalent or superior to benzocaine. Benzocaine use is <strong>not</strong> recommended in children because of the risk of toxicity. (See <a class="local">'Viscous lidocaine'</a> below and <a class="local">'Benzocaine'</a> below.) </p><p>Although evidence is lacking regarding the use of topical anesthetics in children undergoing nasopharyngoscopy, trials in adults indicate, at most, a small reduction in pain over vasoconstrictor medication and lubricants [<a href="#rid44">44</a>]. By contrast, topical anesthetics significantly reduce pain and gagging during nasogastric tube placement in adults and, when used with close attention to dose, may be beneficial in children undergoing this procedure [<a href="#rid45">45-47</a>].</p><p>Evidence does <strong>not</strong> support the routine use of topical anesthetics (eg, viscous <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>) during minor procedures involving the urethra or the oropharynx in children because of limited efficacy and the potential risk of local anesthetic toxicity or methemoglobinemia. For example, viscous lidocaine does <strong>not</strong> significantly reduce the pain of urethral catheterization in infants compared with lubricant alone [<a href="#rid48">48,49</a>]. Viscous lidocaine also has limited impact on reducing the pain of intraoral lesions caused by herpetic gingivostomatitis when compared with placebo gel which may be a proxy for its efficacy for pain control during repair of intraoral lacerations [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/6339.html" rel="external">"Urine collection techniques in infants and children with suspected urinary tract infection", section on 'Transurethral bladder catheterization'</a> and  <a class="medical medical_review" href="/d/html/6046.html" rel="external">"Herpetic gingivostomatitis in young children", section on '"Magic mouthwash" and other topical therapies'</a>.)</p><p>The use of topical anesthetics for awake intubation is discussed separately. (See  <a class="medical medical_review" href="/d/html/14929.html" rel="external">"Clinical use of local anesthetics in anesthesia", section on 'Topical anesthetics'</a>.)</p><p class="headingAnchor" id="H929621702"><span class="h2">Use in neonates</span><span class="headingEndMark"> — </span>The use of topical anesthetics for pain control in neonates is discussed separately. (See  <a class="medical medical_review" href="/d/html/5018.html" rel="external">"Management and prevention of pain in neonates", section on 'Topical anesthetics'</a>.) </p><p class="headingAnchor" id="H3512703984"><span class="h1">AGENTS FOR INTACT SKIN</span></p><p class="headingAnchor" id="H11"><span class="h2">Lidocaine-prilocaine</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">Lidocaine-prilocaine</a> (eg, EMLA [an acronym for "eutectic mixture of local anesthetics"], Oraqix, Lidopril, Priloxx) consists of 2.5%<a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> and 2.5% <a class="drug drug_general" data-topicid="10228" href="/d/drug information/10228.html" rel="external">prilocaine</a> in a cream base. A eutectic mixture has a lower melting point than its individual components; consequently, it is in liquid form at room temperature [<a href="#rid51">51,52</a>]. The anesthetics in lidocaine-prilocaine cream are concentrated in micron-sized droplets. The small size of the droplets and the high concentration gradient promote penetration of the anesthetic through intact skin [<a href="#rid51">51,53</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose </strong>– Typical dosing for venipuncture is as follows: Apply 1 to 2 g of <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> cream per 10 cm<sup>2</sup> of skin in infants and children three months of age or older and who weigh at least 5 kg. Lidocaine-prilocaine is supplied as a 5 g or 30 g tube. Estimation of dose is easier with the smaller tube. Typical application involves placing lidocaine-prilocaine on two sites prior to the procedure; the preferred site and a back-up site in case the first attempt is unsuccessful. </p><p></p><p class="bulletIndent1">The cream should be covered with an occlusive dressing (eg, gauze with tape or adhesive polyurethane film dressing [eg, Tegaderm or Opsite]) for 45 to 60 minutes. </p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">Lidocaine-prilocaine</a> cream requires approximately one hour to achieve peak effect. In one study, the depth of anesthesia measured by needle insertion was approximately 3 mm one hour after application to intact skin; maximum penetration was 5 mm after 1.5 to 2 hours. The depth of anesthesia penetration continued to increase for 30 to 60 minutes after removal of the cream. Lidocaine-prilocaine effectively reduces pain for at least 1 to 2 hours after removal of the cream. The duration of action can last as long as four hours [<a href="#rid2">2,51,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and adverse effects</strong> – Contraindications to the use of prilocaine-lidocaine include conditions requiring rapid treatment, known sensitivity to <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="10228" href="/d/drug information/10228.html" rel="external">prilocaine</a>, or other amide type anesthetics; congenital or idiopathic methemoglobinemia, and, in infants 12 months of age and younger, predisposition to methemoglobinemia such as glucose-6-phosphate dehydrogenase deficiency or concurrent use of methemoglobin-inducing medications  (<a class="graphic graphic_table graphicRef51406" href="/d/graphic/51406.html" rel="external">table 4</a>) [<a href="#rid17">17,55</a>]. </p><p></p><p class="bulletIndent1">Adverse reactions associated with <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> cream include mild, transient skin irritation and methemoglobinemia attributable to the <a class="drug drug_general" data-topicid="10228" href="/d/drug information/10228.html" rel="external">prilocaine</a> in the formulation [<a href="#rid17">17,56</a>]. With appropriate application, plasma concentrations of the anesthetics are low, and the increase in methemoglobin level is negligible [<a href="#rid17">17,56</a>]. However, cases of methemoglobinemia, seizures, and respiratory depression have been described with excessive skin application in children, including those patients with skin conditions that may have increased systemic absorption, such as atopic dermatitis [<a href="#rid56">56-58</a>]. Methemoglobinemia is also more likely to occur in infants younger than three months of age and in children with a predisposing condition, such as glucose-6-phosphate dehydrogenase deficiency or concurrent use of methemoglobin-inducing medications  (<a class="graphic graphic_table graphicRef51406" href="/d/graphic/51406.html" rel="external">table 4</a>) [<a href="#rid17">17,56,58</a>]. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia"</a>.)</p><p></p><p class="bulletIndent1">Contact dermatitis may rarely occur following <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> application [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Liposomal lidocaine</span><span class="headingEndMark"> — </span>Liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> (eg, LMX [formerly known as ELA-Max]) consists of topical preparation of lidocaine encapsulated in liposomes. LMX may be followed by a numeral, such as LMX 4 or LMX 5, which indicates the percent strength of lidocaine in the preparation. Liposomes facilitate the rate and extent of drug absorption and protect the drug from being rapidly metabolized [<a href="#rid18">18</a>]. This product is available without a prescription. In contrast to <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a>, application of liposomal lidocaine does <strong>not</strong> require an occlusive dressing and the recommended duration of treatment is 30 rather than 60 minutes. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – When used for intravenous (IV) access or venipuncture, 1 to 2.5 g of LMX-4 cream (4% <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>) can be applied to 6.25 cm<sup>2</sup> of skin in infants and children older than one month of age [<a href="#rid60">60,61</a>]. Liposomal lidocaine is supplied as a 5 g, 15 g, and 30 g tube. Estimation of dose is easier with the smaller tube. Typical application involves placing <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> on two sites prior to the procedure; the preferred site and a back-up site in case the first attempt is unsuccessful. </p><p></p><p class="bulletIndent1">LMX-4 should be applied 30 minutes before the procedure. The area does not need to be covered for effective analgesia; however, active children could disrupt the cream and covering the area with a polyurethane dressing (eg, Tegaderm or Opsite) may be protective. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and adverse effects</strong> – As described above for <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a>, liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> should not be used in patients with lidocaine or amide anesthetic allergy. Lidocaine toxicity (arrhythmias, seizures, coma, and death) may occur if liposomal lidocaine is applied to large areas of the skin for prolonged periods of time or applied to broken skin, rashes, or areas of skin irritation. Thus, clinicians should ensure that liposomal lidocaine is applied to limited areas of intact skin for the proper amount of time. (See <a class="local">'Lidocaine-prilocaine'</a> above.)</p><p></p><p class="bulletIndent1">No serious adverse events have been described with routine use of liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> [<a href="#rid18">18</a>]. In addition, no clinically significant systemic absorption of lidocaine was apparent among 10 children, 3 to 15 years of age, when serum lidocaine concentrations were measured after a 60-minute application. Safety data is lacking for infants and children younger than two years of age. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia"</a> and  <a class="medical medical_review" href="/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics", section on 'Lidocaine'</a>.)</p><p></p><p class="headingAnchor" id="H24"><span class="h2">Tetracaine gel</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">Tetracaine</a> gel (eg, Ametop) contains 40 mg of tetracaine per 1 g of gel (4 percent weight/weight) and is widely used outside of the United States. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – Apply 1 g per 6.25 cm<sup>2</sup> of skin and cover with an occlusive dressing (eg, gauze with tape or adhesive polyurethane film dressing [eg, Tegaderm or Opsite]) for 30 to 45 minutes [<a href="#rid21">21</a>]. <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">Tetracaine</a> gel is supplied as a 1.5 g tube that delivers 1 g of drug when squeezed. </p><p></p><p class="bulletIndent1">Duration of action approaches four to six hours. Skin erythema is a normal consequence of tetracaine-induced capillary dilation and may assist in venous cannulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications and precautions</strong> – <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">Tetracaine</a> gel should <strong>not</strong> be used in premature infants, full term infants under one month of age, and patients with ester anesthetic allergy. Cardiac arrhythmias, including wide complex tachycardia and reversible hemodynamic instability, have been reported when tetracaine was applied to the antecubital fossa for an IV access procedure in a two day old premature infant [<a href="#rid62">62</a>]. </p><p></p><p class="headingAnchor" id="H3716912575"><span class="h2">Self-heating lidocaine and tetracaine topical patch</span><span class="headingEndMark"> — </span>The self-heating <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> and <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> patch (Synera, Pliaglis) contains 70 mg lidocaine and 70 mg tetracaine [<a href="#rid1">1</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – Apply one patch to intact skin for 20 to 30 minutes and promptly remove. After one failed attempt, one additional patch may be applied in children [<a href="#rid63">63</a>]. Simultaneous application of more than one patch is not recommended in children. The top cover of the patch should not be cut or removed because this action may lead to burn injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and adverse effects</strong> – The patch should <strong>not</strong> be used in patients with sensitivity to amide or ester local anesthetics or para-aminobenzoic acid hypersensitivity [<a href="#rid63">63</a>]. The heating element contains iron. Thus, the patch must be removed before some diagnostic procedures, especially magnetic resonance imaging.</p><p></p><p class="bulletIndent1">Prolonged application of the patch to intact skin or application to broken skin or mucous membranes may result in serious local anesthetic toxicity including seizures, cardiac arrhythmias, and methemoglobinemia [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">Approximately 90 percent of the drug content remains in the patch after use.</p><p></p><p class="bulletIndent1">With routine use, redness and local swelling of the skin at the application site may occur but should rapidly resolve after the patch is removed.</p><p></p><p class="headingAnchor" id="H4091562025"><span class="h2">Needle-free lidocaine delivery</span><span class="headingEndMark"> — </span>Another method of <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> delivery uses compressed gas to deliver a liquid form of lidocaine (J-Tip Needleless Injection System).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – This device administers 2 to 2.5 mg (0.2 to 0.25 mL of a buffered 1% <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> solution) utilizing a carbon dioxide cartridge [<a href="#rid1">1</a>]. The device is supplied separately from the drug and is filled by a pharmacist and stored at room temperature or filled at the bedside by the provider just prior to administration. The manufacturer suggests the use of 1% buffered lidocaine or preservative-free lidocaine without <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> to minimize any burning or stinging. The clinician should consult the device manufacturer's instructions for details on usage [<a href="#rid64">64</a>]. The provider should ensure that the device is not applied directly over a vein during administration. Analgesia is typically achieved within 1 to 3 minutes.</p><p></p><p class="bulletIndent1">The pain of administration with a this device is low [<a href="#rid25">25,27,28</a>], and its use does not impact first-attempt success rate [<a href="#rid65">65</a>]. The system produces an audible "pop" when deployed that may cause additional anxiety in the patient [<a href="#rid27">27</a>]. In one trial of 197 children, carbon dioxide-propelled <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> was no more effective than carbon dioxide-propelled isotonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> for managing the pain of needle insertion suggesting that the analgesia achieved within 1 to 2 minutes may derive more from the physical effects of subcutaneous fluid injection rather than direct effects of the drug [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent1">The cost of a single device relative to a single application of <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> or liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> is comparable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and adverse effects</strong> – Patients with a known allergy to <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> or other amide anesthetics should not receive lidocaine analgesia.</p><p></p><p class="bulletIndent1">Elevated serum <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> levels have been described in patients undergoing analgesia with the J-tip system for peripheral IV access [<a href="#rid66">66</a>]. However, serious lidocaine toxicity, although theoretical possible, has not been reported.</p><p></p><p class="headingAnchor" id="H3970302459"><span class="h2">Vapocoolant spray</span><span class="headingEndMark"> — </span>These agents act by surface cooling of the skin immediately prior to venipuncture, IV placement, or intramuscular (IM) shot [<a href="#rid1">1</a>]. Local cooling may desensitize skin pain receptors and/or inhibit spinal cord pain signals by a specific cold temperature nerve impulse.</p><p><a class="drug drug_general" data-topicid="8930" href="/d/drug information/8930.html" rel="external">Ethyl chloride</a>, a flammable anesthetic, is the most studied vapocoolant spray. It is also combined with dichlorotetrafluoroethane in a prescription freezing spray (eg, Fluro-Ethyl) [<a href="#rid1">1</a>]. Other products (Pain Ease, Instant Ice) utilize 1,1,1,3,3,-pentafluoropropane and 1,1,1,2,-tetrafluoroethane in spray form which is not flammable or ozone depleting. Ethyl chloride should be used on intact skin and may be used in patients with cellulitis or other lesions. 1,1,1,3,3,-pentafluoropropane with 1,1,1,2,-tetrafluoroethane (eg, Pain Ease, Instant Ice) is designed for use on intact skin, minor open wounds, and intact mucous membranes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – The goal is to spray long enough to cause skin blanching without freezing. Spraying should cease as soon as the skin blanches to avoid frostbite.</p><p></p><p class="bulletIndent1">For <a class="drug drug_general" data-topicid="8930" href="/d/drug information/8930.html" rel="external">ethyl chloride</a> liquid, application is generally three to seven seconds [<a href="#rid67">67</a>]. For mist sprays, application is up to 10 seconds. The distance from the skin surface should be 3 to 9 inches during administration. Once blanching is achieved, analgesia lasts approximately 60 seconds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and contraindications</strong> – <a class="drug drug_general" data-topicid="8930" href="/d/drug information/8930.html" rel="external">Ethyl chloride</a> should not be used near open flames or electrocautery [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1">Vapocoolant sprays are not recommended in diabetics or patients with poor circulation or insensitive skin. Vapocoolant sprays should not be administered to patients with allergies to spray components (eg, <a class="drug drug_general" data-topicid="8930" href="/d/drug information/8930.html" rel="external">ethyl chloride</a>, 1,1,1,3,3,-pentafluoropropane, or 1,1,1,2,-tetrafluoroethane) [<a href="#rid68">68</a>]. Care should be taken to avoid eye contact during vapocoolant spray application because of potential for chemical irritation.</p><p></p><p class="bulletIndent1">Freezing may alter skin pigmentation [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Inhalation of products that contain <a class="drug drug_general" data-topicid="8930" href="/d/drug information/8930.html" rel="external">ethyl chloride</a> may produce narcotic and general anesthetic effects including coma with depression of respiration and cardiac activity.</p><p></p><p class="headingAnchor" id="H3546165167"><span class="h2">Lidocaine iontophoresis</span><span class="headingEndMark"> — </span>Iontophoresis uses an electric current from two externally placed electrodes to move ionized <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> across the stratum corneum barrier to the dermis, where it blocks nerve endings [<a href="#rid9">9</a>]. The rate of anesthetic transport is higher with iontophoresis than passive diffusion [<a href="#rid10">10,11,34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">Lidocaine</a> is administered in a volume of 0.6 to 1.0 mL of 2% lidocaine with <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>. The electric current delivered is titrated from 0 to a maximum of 4 milliamperes (mA). A current of 0.2 mA/cm<sup>2</sup> applied for 10 minutes achieves an anesthetic depth of 5 to 7 mm [<a href="#rid69">69</a>]. Delivery of the drug is proportional to the product of the electric current and the application time [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">The onset of anesthesia occurs approximately 10 to 20 minutes after administration begins [<a href="#rid34">34</a>]. The duration is approximately 30 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and adverse effects</strong> – <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">Lidocaine</a> iontophoresis should not be used in patients with sensitivity to lidocaine or other amide anesthetics or with lesions near the eye [<a href="#rid10">10,34</a>]. In addition, it should not be used over metal indwelling catheters or in patients with pacemakers.</p><p></p><p class="bulletIndent1">Adverse effects of iontophoresis are limited to local skin reactions, such as transient erythema, urticaria, blisters, and superficial burns [<a href="#rid10">10,11</a>]. Tingling, burning, and/or itching sensations may occur under the electrodes. <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">Lidocaine</a> toxicity has not been reported.</p><p></p><p class="headingAnchor" id="H1878500591"><span class="h1">AGENTS FOR LACERATION REPAIR</span></p><p class="headingAnchor" id="H2971926097"><span class="h2">Lidocaine-epinephrine-tetracaine (LET)</span><span class="headingEndMark"> — </span>LET is a combination of <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> (4%), <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> (0.1%), and <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> (0.5%) available as an aqueous solution or methylcellulose-based gel. The dose, application, and adverse effects are as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and application</strong> – LET in a dose of 1 to 3 mL is applied to an open wound for 20 to 30 minutes. The method of application depends upon whether gel or solution is being applied: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gel – Gels are applied to the wound and wound edges with a cotton-tipped applicator [<a href="#rid36">36,38</a>]. The wound is then covered with sterile gauze held in place by an adhesive dressing, tape, or an elastic wrap for 20 to 30 minutes. The gel is removed before suturing. The duration of action following removal of the anesthetic is 45 to 60 minutes [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent2">Gels provide similar anesthesia to aqueous solutions but offer practical advantages. In one study of suturing of uncomplicated scalp and facial lacerations in 200 children, more patients treated with gel had complete anesthesia (85 versus 76 percent) and fewer had partial anesthesia (5 versus 21 percent), although more had incomplete anesthesia (9 versus 3 percent), compared with the solution [<a href="#rid38">38</a>]. In addition, problems seen with the solution, such as difficulty in application, loss of anesthetic volume due to drainage from the laceration, and inadvertent contact with mucous membranes, are less likely with the gel.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Solution – The aqueous solution of LET is first painted into the wound with a cotton-tipped swab. This application is then be repeated every 3 to 5 minutes [<a href="#rid37">37,38</a>]. Anesthesia becomes effective in approximately 20 to 30 minutes.</p><p></p><p class="bulletIndent2">Alternatively, a saturated cotton ball can be applied directly to the laceration after initial application and held in place with tape although experience suggests that this method may not be as effective, especially for deep or oozing wounds. </p><p></p><p class="bulletIndent2">The clinician should ensure that the solution does not come in contact with mucous membranes.</p><p></p><p class="bulletIndent1">The use of up to 3 mL of LET gel or solution as described is supported by extensive clinical experience with this dose without reported serious adverse effects. As an example, in a trial of 203 children between the ages of three months to 17 years receiving 3 mL of LET prior to wound closure with tissue adhesives, no serious toxicity occurred in any patient [<a href="#rid70">70</a>]. Although the administered dose of <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> in 3 mL of LET is approximately 135 mg, the amount of lidocaine and <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> actually absorbed is limited by the size of the laceration and the presence of <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>. Much larger topical doses of lidocaine without epinephrine (up to 90 mg/kg) have been tolerated in adults with partial thickness burns without serious toxicity although the plasma concentration of lidocaine (5.8 mcg/mL) was above the therapeutic level [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1">Weight-based dosing has been suggested for children &lt;17 kg (eg, 0.175 mL/kg) to prevent application of &gt;5 mg/kg of <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> [<a href="#rid31">31</a>]. This approach appears conservative given the lack of toxicity associated with the use of LET; evidence is lacking to indicate that weight-based dosing is needed.</p><p></p><p class="bulletIndent1">Alternatively, clinicians can use dosing guidance as for other local anesthetic formulations. However, LET is likely to have lower potential for systemic absorption than these agents due to epinephrine-induced vasoconstriction. (See <a class="local">'Liposomal lidocaine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and</strong> <strong>adverse effects</strong> – Contraindications to the use of LET include allergy to amide or ester topical anesthetics. Because of the higher potential for systemic absorption of topical agents in neonates and the theoretical risk of methemoglobinemia posed by the <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> component, LET should be used with caution in infants younger than one month of age.</p><p></p><p class="bulletIndent1">Adverse effects arise from excessive absorption of <a class="drug drug_pediatric" data-topicid="13027" href="/d/drug information/13027.html" rel="external">lidocaine-tetracaine</a>, resulting in systemic toxicity often after mucous membrane exposure or ingestion of a large dose. Adverse effects are rare if recommended doses are not exceeded and application to mucous membranes is avoided [<a href="#rid36">36</a>]. For example, a systematic review of 23 randomized controlled trials in 3218 patients that assessed multiple topical anesthetics, including LET, found no reports of serious complications [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1">Toxicity of <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> and <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> include central nervous system (CNS) symptoms manifests with headache, irritability, restlessness, metallic taste, tingling around the lips, somnolence, blurred vision, and seizures. Cardiovascular toxicity consist of bradycardia, decreased contractility, atrioventricular block, vasodilation, ventricular ectopy, and cardiac arrest [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/d/html/90613.html" rel="external">"Local anesthetic systemic toxicity", section on 'Clinical presentation of toxicity'</a>.) </p><p></p><p class="bulletIndent1">Methemoglobinemia has rarely been reported in association with the use of topical <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Acquired methemoglobinemia'</a>.)</p><p></p><p class="headingAnchor" id="H1801952547"><span class="h2">Tetracaine-adrenaline-cocaine (TAC)</span><span class="headingEndMark"> — </span>TAC is a combination of <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> (0.25 to 0.5%), adrenaline (<a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>, 0.025 to 0.05 percent), and cocaine (4 to 11.8 percent). It is available as a solution or gel. Tetracaine and cocaine provide topical anesthesia [<a href="#rid35">35,37</a>]. Cocaine and adrenaline cause local vasoconstriction that limits systemic absorption and minimizes bleeding.</p><p>TAC was among the first topical anesthetics developed. It is comparable to <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> infiltration in providing anesthesia for scalp and facial lacerations, and has been widely used for laceration repair in pediatric patients [<a href="#rid35">35,72,74</a>].</p><p>TAC is safe if used correctly. However, misapplication or mucous membrane exposure may result in serious systemic toxicity such as hyperexcitability, seizures, stroke, cerebral hemorrhage, tachycardia, arrhythmias, malignant hypertension, and cardiac arrest [<a href="#rid5">5,17,36</a>]. In addition, cocaine is a controlled substance with the potential for misuse. Its cost far exceeds that of <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> [<a href="#rid37">37,72</a>]. As a result, TAC has largely been replaced by other topical anesthetics with similar efficacy, primarily LET [<a href="#rid5">5,13,37,38</a>].</p><p class="headingAnchor" id="H1408582248"><span class="h1">AGENTS FOR MUCOSAL SURFACES</span></p><p class="headingAnchor" id="H40721994"><span class="h2">Viscous lidocaine</span><span class="headingEndMark"> — </span>Viscous <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, available as in a 2% concentration (20 mg/mL), is the most commonly used mucosal anesthetic preparation in children.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – For application to mucosal surfaces, do not exceed 4 mg/kg (0.2 mL/kg of the 2% [20 mg/mL] concentration).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and adverse effects</strong> – Viscous <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> should <strong>not</strong> be used in patients with lidocaine or amide anesthetic allergy.</p><p></p><p class="bulletIndent1">As with other lidocaine-containing preparations, <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> toxicity (arrhythmias, seizures, coma, and death) and, rarely, methemoglobinemia may occur if an excessive dose of viscous lidocaine is administered [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H3917260122"><span class="h2">Benzocaine</span><span class="headingEndMark"> — </span>Benzocaine-containing sprays or gels should be <strong>avoided</strong> in children [<a href="#rid76">76</a>]. Alternative agents, such as <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> spray or 2% viscous lidocaine are much less likely to cause methemoglobinemia and appear to have similar efficacy. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Topical anesthetics'</a>.)</p><p class="headingAnchor" id="H298036845"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/130229.html" rel="external">"Society guideline links: Topical anesthetics in children"</a>.)</p><p class="headingAnchor" id="H45"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Topical analgesics, either topical anesthetics or vapocoolant spray, can be applied without needles and can reduce the need for physical restraint or sedation for minor procedures. They also avoid the tissue distortion that occurs with infiltrated anesthetics. (See <a class="local">'Selection of a topical agent'</a> above and <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1">Prior to minor painful procedures, nonpharmacologic interventions (eg, behavioral techniques, cognitive techniques  (<a class="graphic graphic_table graphicRef50950" href="/d/graphic/50950.html" rel="external">table 1</a>)) are essential adjuncts to topical analgesia. They help attenuate pain in the conscious child and enhance the benefit of local analgesia. (See  <a class="medical medical_review" href="/d/html/6330.html" rel="external">"Procedural sedation in children: Approach", section on 'Nonpharmacologic interventions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preparation</strong> – Before applying topical anesthetics, the provider should ensure that the patient has no known allergy to <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a>, or other amide- or ester-type anesthetics. Although toxicity is rare and typically associated with excessive application, providers should understand the signs and symptoms of local anesthetic toxicity and know the appropriate management. The table provides signs and symptoms and recommended management of seizures and cardiotoxicity in patients with systemic toxicity from local anesthetics  (<a class="graphic graphic_table graphicRef107887" href="/d/graphic/107887.html" rel="external">table 2</a>). (See <a class="local">'Preparation'</a> above.) </p><p></p><p class="bulletIndent1">Selected agents (eg, <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="10228" href="/d/drug information/10228.html" rel="external">prilocaine</a>, and <a class="drug drug_pediatric" data-topicid="13008" href="/d/drug information/13008.html" rel="external">benzocaine</a>) also have the potential to cause methemoglobinemia, and the provider should be aware of clinical features and treatment of methemoglobinemia. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical anesthesia by indication</strong> – Topical anesthesia is effect for a variety of procedures: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vascular access or venipuncture</strong> – The approach to topical analgesia for vascular access or venipuncture varies for nonurgent or urgent procedures (see <a class="local">'Vascular access or venipuncture'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Whenever available, children should be offered some form of topical analgesia prior to nonurgent venipuncture, intravenous (IV) catheter placement, or percutaneous access of an indwelling central line. For these patients, we suggest liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> gel, <a class="drug drug_pediatric" data-topicid="12553" href="/d/drug information/12553.html" rel="external">lidocaine-prilocaine</a> cream, a heated lidocaine and tetracaine patch  (<a class="graphic graphic_table graphicRef117407" href="/d/graphic/117407.html" rel="external">table 3</a>), or needle-free lidocaine administration rather than vapocoolant spray or lidocaine iontophoresis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For awake patients who are undergoing urgent venipuncture, IV catheter placement or percutaneous access of an indwelling central line, we suggest analgesia by needle-free <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a> delivery or local infiltration of 1% buffered lidocaine solution via a 30-gauge needle, depending upon patient and caregiver preference, rather than administration of vapocoolant spray (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IM injections</strong> – For infants and children undergoing nonurgent intramuscular (IM) injections, we suggest analgesia with topical anesthetics (prilocaine-lidocaine, liposomal <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>, or <a class="drug drug_pediatric" data-topicid="12828" href="/d/drug information/12828.html" rel="external">tetracaine</a> gel) rather than vapocoolant spray or other cooling methods (eg, application of an ice pack) prior to IM injections (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Intramuscular injections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laceration repair</strong> – For patients with uncomplicated facial or scalp lacerations &lt;5 cm in length, we suggest initial pain control with topical LET (lidocaine-epinephrine-tetracaine) rather than injected local anesthetic (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Laceration repair'</a> above and <a class="local">'Lidocaine-epinephrine-tetracaine (LET)'</a> above.)</p><p></p><p class="bulletIndent2">LET is available in an aqueous solution and a <a class="drug drug_pediatric" data-topicid="135074" href="/d/drug information/135074.html" rel="external">methylcellulose</a> based gel. The gel is preferred because it maintains better contact with the open wound and is easier to apply. In addition, LET may reduce the pain of local infiltration of anesthetics for lacerations on other parts of the body with the exception of sites near mucus membranes, poorly vascularized sites (eg, auricle), or genitalia where placement of LET is contraindicated. However, it does not typically provide complete analgesia. (See <a class="local">'Lidocaine-epinephrine-tetracaine (LET)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dental and nasopharyngeal procedures</strong> – Application of topical anesthetics to mucosal surfaces reduces the pain of intraoral dental injections and may be helpful for nasopharyngeal procedures, such as nasopharyngoscopy and nasogastric tube placement. In children, evidence does <strong>not</strong> support the routine use of topical anesthetics (eg, viscous <a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">lidocaine</a>) during minor procedures involving the urethra or the oropharynx because of limited efficacy and the potential risk of local anesthetic toxicity or methemoglobinemia. (See <a class="local">'Mucosal surfaces'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Options for minimal sedation</strong> – In many children undergoing minimally painful procedures, local anesthetics can be delivered topically to diminish or abolish the pain without the need for sedation, especially when age-appropriate nonpharmacologic interventions are used. When nonpharmacologic interventions and topical anesthetics are <strong>not</strong> sufficient and minimal sedation is necessary, inhaled <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> or intranasal <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> are suggested. (See  <a class="medical medical_review" href="/d/html/85542.html" rel="external">"Procedural sedation in children: Selection of medications", section on 'Minimally painful procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standing orders</strong> – Emergency department (ED) standing orders in triage permit nurses to place topical anesthetics on children likely to undergo dermal procedures or laceration repair and are utilized in many hospitals  (<a class="graphic graphic_algorithm graphicRef67047" href="/d/graphic/67047.html" rel="external">algorithm 1</a>). (See <a class="local">'Standing orders'</a> above and <a class="local">'Standing orders'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zempsky WT. Pharmacologic approaches for reducing venous access pain in children. Pediatrics 2008; 122 Suppl 3:S140.</a></li><li><a class="nounderline abstract_t">Cordoni A, Cordoni LE. Eutectic mixture of local anesthetics reduces pain during intravenous catheter insertion in the pediatric patient. Clin J Pain 2001; 17:115.</a></li><li><a class="nounderline abstract_t">Goldman RD, Koren G. Biologic markers of pain in the vulnerable infant. Clin Perinatol 2002; 29:415.</a></li><li><a class="nounderline abstract_t">Hollander JE, Singer AJ. Laceration management. Ann Emerg Med 1999; 34:356.</a></li><li><a class="nounderline abstract_t">Smith GA, Strausbaugh SD, Harbeck-Weber C, et al. Comparison of topical anesthetics without cocaine to tetracaine-adrenaline-cocaine and lidocaine infiltration during repair of lacerations: bupivacaine-norepinephrine is an effective new topical anesthetic agent. Pediatrics 1996; 97:301.</a></li><li><a class="nounderline abstract_t">Griffith RJ, Jordan V, Herd D, et al. Vapocoolants (cold spray) for pain treatment during intravenous cannulation. Cochrane Database Syst Rev 2016; 4:CD009484.</a></li><li><a class="nounderline abstract_t">Cohen Reis E, Holubkov R. Vapocoolant spray is equally effective as EMLA cream in reducing immunization pain in school-aged children. Pediatrics 1997; 100:E5.</a></li><li><a class="nounderline abstract_t">Farion KJ, Splinter KL, Newhook K, et al. The effect of vapocoolant spray on pain due to intravenous cannulation in children: a randomized controlled trial. CMAJ 2008; 179:31.</a></li><li><a class="nounderline abstract_t">Galinkin JL, Rose JB, Harris K, Watcha MF. Lidocaine iontophoresis versus eutectic mixture of local anesthetics (EMLA) for IV placement in children. Anesth Analg 2002; 94:1484.</a></li><li><a class="nounderline abstract_t">Kim MK, Kini NM, Troshynski TJ, Hennes HM. A randomized clinical trial of dermal anesthesia by iontophoresis for peripheral intravenous catheter placement in children. Ann Emerg Med 1999; 33:395.</a></li><li><a class="nounderline abstract_t">Zempsky WT, Anand KJ, Sullivan KM, et al. Lidocaine iontophoresis for topical anesthesia before intravenous line placement in children. J Pediatr 1998; 132:1061.</a></li><li><a class="nounderline abstract_t">Squire SJ, Kirchhoff KT, Hissong K. Comparing two methods of topical anesthesia used before intravenous cannulation in pediatric patients. J Pediatr Health Care 2000; 14:68.</a></li><li><a class="nounderline abstract_t">Zempsky WT, Karasic RB. EMLA versus TAC for topical anesthesia of extremity wounds in children. Ann Emerg Med 1997; 30:163.</a></li><li><a class="nounderline abstract_t">Halperin DL, Koren G, Attias D, et al. Topical skin anesthesia for venous, subcutaneous drug reservoir and lumbar punctures in children. Pediatrics 1989; 84:281.</a></li><li><a class="nounderline abstract_t">Lander J, Hodgins M, Nazarali S, et al. Determinants of success and failure of EMLA. Pain 1996; 64:89.</a></li><li><a class="nounderline abstract_t">Young SS, Schwartz R, Sheridan MJ. EMLA cream as a topical anesthetic before office phlebotomy in children. South Med J 1996; 89:1184.</a></li><li><a class="nounderline abstract_t">Berde CB. Toxicity of local anesthetics in infants and children. J Pediatr 1993; 122:S14.</a></li><li><a class="nounderline abstract_t">Eichenfield LF, Funk A, Fallon-Friedlander S, Cunningham BB. A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children. Pediatrics 2002; 109:1093.</a></li><li><a class="nounderline abstract_t">Kleiber C, Sorenson M, Whiteside K, et al. Topical anesthetics for intravenous insertion in children: a randomized equivalency study. Pediatrics 2002; 110:758.</a></li><li><a class="nounderline abstract_t">Koh JL, Harrison D, Myers R, et al. A randomized, double-blind comparison study of EMLA and ELA-Max for topical anesthesia in children undergoing intravenous insertion. Paediatr Anaesth 2004; 14:977.</a></li><li><a class="nounderline abstract_t">O'Brien L, Taddio A, Lyszkiewicz DA, Koren G. A critical review of the topical local anesthetic amethocaine (Ametop) for pediatric pain. Paediatr Drugs 2005; 7:41.</a></li><li><a class="nounderline abstract_t">Newbury C, Herd DW. Amethocaine versus EMLA for successful intravenous cannulation in a children's emergency department: a randomised controlled study. Emerg Med J 2009; 26:487.</a></li><li><a class="nounderline abstract_t">Lander JA, Weltman BJ, So SS. EMLA and amethocaine for reduction of children's pain associated with needle insertion. Cochrane Database Syst Rev 2006; :CD004236.</a></li><li><a class="nounderline abstract_t">Cozzi G, Borrometi F, Benini F, et al. First-time success with needle procedures was higher with a warm lidocaine and tetracaine patch than an eutectic mixture of lidocaine and prilocaine cream. Acta Paediatr 2017; 106:773.</a></li><li><a class="nounderline abstract_t">Zempsky WT, Robbins B, Richards PT, et al. A novel needle-free powder lidocaine delivery system for rapid local analgesia. J Pediatr 2008; 152:405.</a></li><li><a class="nounderline abstract_t">Zempsky WT, Bean-Lijewski J, Kauffman RE, et al. Needle-free powder lidocaine delivery system provides rapid effective analgesia for venipuncture or cannulation pain in children: randomized, double-blind Comparison of Venipuncture and Venous Cannulation Pain After Fast-Onset Needle-Free Powder Lidocaine or Placebo Treatment trial. Pediatrics 2008; 121:979.</a></li><li><a class="nounderline abstract_t">Jimenez N, Bradford H, Seidel KD, et al. A comparison of a needle-free injection system for local anesthesia versus EMLA for intravenous catheter insertion in the pediatric patient. Anesth Analg 2006; 102:411.</a></li><li><a class="nounderline abstract_t">Spanos S, Booth R, Koenig H, et al. Jet Injection of 1% buffered lidocaine versus topical ELA-Max for anesthesia before peripheral intravenous catheterization in children: a randomized controlled trial. Pediatr Emerg Care 2008; 24:511.</a></li><li><a class="nounderline abstract_t">Auerbach M, Tunik M, Mojica M. A randomized, double-blind controlled study of jet lidocaine compared to jet placebo for pain relief in children undergoing needle insertion in the emergency department. Acad Emerg Med 2009; 16:388.</a></li><li><a class="nounderline abstract_t">Zempsky WT, Cravero JP, American Academy of Pediatrics Committee on Pediatric Emergency Medicine and Section on Anesthesiology and Pain Medicine. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics 2004; 114:1348.</a></li><li><a class="nounderline abstract_t">Fein JA, Zempsky WT, Cravero JP, et al. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics 2012; 130:e1391.</a></li><li><a class="nounderline abstract_t">Leahy S, Kennedy RM, Hesselgrave J, et al. On the front lines: lessons learned in implementing multidisciplinary peripheral venous access pain-management programs in pediatric hospitals. Pediatrics 2008; 122 Suppl 3:S161.</a></li><li><a class="nounderline abstract_t">Sridharan K, Sivaramakrishnan G. Pharmacological interventions for reducing pain related to immunization or intramuscular injection in children: A mixed treatment comparison network meta-analysis of randomized controlled clinical trials. J Child Health Care 2018; 22:393.</a></li><li><a class="nounderline abstract_t">Kennedy RM, Luhmann JD. The "ouchless emergency department". Getting closer: advances in decreasing distress during painful procedures in the emergency department. Pediatr Clin North Am 1999; 46:1215.</a></li><li><a class="nounderline abstract_t">Bonadio WA. TAC: a review. Pediatr Emerg Care 1989; 5:128.</a></li><li><a class="nounderline abstract_t">Ernst AA, Marvez E, Nick TG, et al. Lidocaine adrenaline tetracaine gel versus tetracaine adrenaline cocaine gel for topical anesthesia in linear scalp and facial lacerations in children aged 5 to 17 years. Pediatrics 1995; 95:255.</a></li><li><a class="nounderline abstract_t">Schilling CG, Bank DE, Borchert BA, et al. Tetracaine, epinephrine (adrenalin), and cocaine (TAC) versus lidocaine, epinephrine, and tetracaine (LET) for anesthesia of lacerations in children. Ann Emerg Med 1995; 25:203.</a></li><li><a class="nounderline abstract_t">Resch K, Schilling C, Borchert BD, et al. Topical anesthesia for pediatric lacerations: a randomized trial of lidocaine-epinephrine-tetracaine solution versus gel. Ann Emerg Med 1998; 32:693.</a></li><li><a class="nounderline abstract_t">Singer AJ, Stark MJ. Pretreatment of lacerations with lidocaine, epinephrine, and tetracaine at triage: a randomized double-blind trial. Acad Emerg Med 2000; 7:751.</a></li><li><a class="nounderline abstract_t">Singer AJ, Stark MJ. LET versus EMLA for pretreating lacerations: a randomized trial. Acad Emerg Med 2001; 8:223.</a></li><li><a class="nounderline abstract_t">Meechan JG. Effective topical anesthetic agents and techniques. Dent Clin North Am 2002; 46:759.</a></li><li><a class="nounderline abstract_t">Cho SY, Kim E, Park SH, et al. Effect of Topical Anesthesia on Pain from Needle Insertion and Injection and Its Relationship with Anxiety in Patients Awaiting Apical Surgery: A Randomized Double-blind Clinical Trial. J Endod 2017; 43:364.</a></li><li><a class="nounderline abstract_t">Milani AS, Zand V, Abdollahi AA, et al. Effect of Topical Anesthesia with Lidocaine-prilocaine (EMLA) Cream and Local Pressure on Pain during Infiltration Injection for Maxillary Canines: A Randomized Double-blind clinical trial. J Contemp Dent Pract 2016; 17:592.</a></li><li><a class="nounderline abstract_t">Sunkaraneni VS, Jones SE. Topical anaesthetic or vasoconstrictor preparations for flexible fibre-optic nasal pharyngoscopy and laryngoscopy. Cochrane Database Syst Rev 2011; :CD005606.</a></li><li><a class="nounderline abstract_t">Singer AJ, Konia N. Comparison of topical anesthetics and vasoconstrictors vs lubricants prior to nasogastric intubation: a randomized, controlled trial. Acad Emerg Med 1999; 6:184.</a></li><li><a class="nounderline abstract_t">Uri O, Yosefov L, Haim A, et al. Lidocaine gel as an anesthetic protocol for nasogastric tube insertion in the ED. Am J Emerg Med 2011; 29:386.</a></li><li><a class="nounderline abstract_t">Kuo YW, Yen M, Fetzer S, Lee JD. Reducing the pain of nasogastric tube intubation with nebulized and atomized lidocaine: a systematic review and meta-analysis. J Pain Symptom Manage 2010; 40:613.</a></li><li><a class="nounderline abstract_t">Chua ME, Firaza PNB, Ming JM, et al. Lidocaine Gel for Urethral Catheterization in Children: A Meta-Analysis. J Pediatr 2017; 190:207.</a></li><li><a class="nounderline abstract_t">Uspal NG, Strelitz B, Gritton J, et al. Randomized Clinical Trial of Lidocaine Analgesia for Transurethral Bladder Catheterization Delivered via Blunt Tipped Applicator in Young Children. Pediatr Emerg Care 2018; 34:273.</a></li><li><a class="nounderline abstract_t">Hopper SM, McCarthy M, Tancharoen C, et al. Topical lidocaine to improve oral intake in children with painful infectious mouth ulcers: a blinded, randomized, placebo-controlled trial. Ann Emerg Med 2014; 63:292.</a></li><li><a class="nounderline abstract_t">Steward DJ. Eutectic mixture of local anesthetics (EMLA): what is it? What does it do? J Pediatr 1993; 122:S21.</a></li><li><a class="nounderline abstract_t">Babich D, Crollick JS. Pediatric dermatologic surgery for the primary care pediatrician. Pediatr Clin North Am 1998; 45:1437.</a></li><li><a class="nounderline abstract_t">Gajraj NM, Pennant JH, Watcha MF. Eutectic mixture of local anesthetics (EMLA) cream. Anesth Analg 1994; 78:574.</a></li><li><a class="nounderline abstract_t">Bjerring P, Arendt-Nielsen L. Depth and duration of skin analgesia to needle insertion after topical application of EMLA cream. Br J Anaesth 1990; 64:173.</a></li><li><a class="nounderline abstract_t">Sinisterra S, Miravet E, Alfonso I, et al. Methemoglobinemia in an infant receiving nitric oxide after the use of eutectic mixture of local anesthetic. J Pediatr 2002; 141:285.</a></li><li><a class="nounderline abstract_t">Elsner P, Dummer R. Signs of methaemoglobinaemia after topical application of EMLA cream in an infant with haemangioma. Dermatology 1997; 195:153.</a></li><li><a class="nounderline abstract_t">Curtis LA, Dolan TS, Seibert HE. Are one or two dangerous? Lidocaine and topical anesthetic exposures in children. J Emerg Med 2009; 37:32.</a></li><li><a class="nounderline abstract_t">Jakobson B, Nilsson A. Methemoglobinemia associated with a prilocaine-lidocaine cream and trimetoprim-sulphamethoxazole. A case report. Acta Anaesthesiol Scand 1985; 29:453.</a></li><li><a class="nounderline abstract_t">Hoss DM, Gross EG, Grant-Kels JM. Histopathology of an adverse reaction to a eutectic mixture of the local anesthetics lidocaine and prilocaine. J Cutan Pathol 1999; 26:100.</a></li><li><a class="nounderline abstract_t">Taddio A, Soin HK, Schuh S, et al. Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trial. CMAJ 2005; 172:1691.</a></li><li><a class="nounderline abstract_t">Sobanko JF, Miller CJ, Alster TS. Topical anesthetics for dermatologic procedures: a review. Dermatol Surg 2012; 38:709.</a></li><li><a class="nounderline abstract_t">Maulidi H, McNair C, Seller N, et al. Arrhythmia associated with tetracaine in an extremely low birth weight premature infant. Pediatrics 2012; 130:e1704.</a></li><li class="breakAll">Synera prescribing information. Galen US Inc, Souderton, PA, 2013. http://www.synera.com/wp-content/uploads/2015/03/SYNERA_PI.pdf.</li><li class="breakAll">J-tip needle free injection system user guide http://jtip.com/resources/user-guide/.</li><li><a class="nounderline abstract_t">Lunoe MM, Drendel AL, Brousseau DC. The use of the needle-free jet injection system with buffered lidocaine device does not change intravenous placement success in children in the emergency department. Acad Emerg Med 2015; 22:447.</a></li><li><a class="nounderline abstract_t">Gulur P, Cohen AR, Watt L, et al. Elevated lidocaine serum concentration after subcutaneous lidocaine administration using a needle-free device in pediatric patients. Pediatr Emerg Care 2014; 30:829.</a></li><li class="breakAll">Gebauer's ethyl chloride. Frequently asked questions. June 2011. https://www.gebauer.com/hs-fs/hub/150313/file-31476793-pdf/docs/ec_acs360_faq.pdf.</li><li class="breakAll">Ethyl chloride product information https://www.gebauer.com/ethylchloride.</li><li><a class="nounderline abstract_t">Irsfeld S, Klement W, Lipfert P. Dermal anaesthesia: comparison of EMLA cream with iontophoretic local anaesthesia. Br J Anaesth 1993; 71:375.</a></li><li><a class="nounderline abstract_t">Harman S, Zemek R, Duncan MJ, et al. Efficacy of pain control with topical lidocaine-epinephrine-tetracaine during laceration repair with tissue adhesive in children: a randomized controlled trial. CMAJ 2013; 185:E629.</a></li><li><a class="nounderline abstract_t">Brofeldt BT, Cornwell P, Doherty D, et al. Topical lidocaine in the treatment of partial-thickness burns. J Burn Care Rehabil 1989; 10:63.</a></li><li><a class="nounderline abstract_t">Tayeb BO, Eidelman A, Eidelman CL, et al. Topical anaesthetics for pain control during repair of dermal laceration. Cochrane Database Syst Rev 2017; 2:CD005364.</a></li><li><a class="nounderline abstract_t">Karim A, Ahmed S, Siddiqui R, Mattana J. Methemoglobinemia complicating topical lidocaine used during endoscopic procedures. Am J Med 2001; 111:150.</a></li><li><a class="nounderline abstract_t">Pryor GJ, Kilpatrick WR, Opp DR. Local anesthesia in minor lacerations: topical TAC vs lidocaine infiltration. Ann Emerg Med 1980; 9:568.</a></li><li><a class="nounderline abstract_t">Smith M, Wolfram W, Rose R. Toxicity--seizures in an infant caused by (or related to) oral viscous lidocaine use. J Emerg Med 1992; 10:587.</a></li><li><a class="nounderline abstract_t">Guay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg 2009; 108:837.</a></li></ol></div><div id="topicVersionRevision">Topic 6338 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978008" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacologic approaches for reducing venous access pain in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11444712" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Eutectic mixture of local anesthetics reduces pain during intravenous catheter insertion in the pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12380466" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Biologic markers of pain in the vulnerable infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459093" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Laceration management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604261" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of topical anesthetics without cocaine to tetracaine-adrenaline-cocaine and lidocaine infiltration during repair of lacerations: bupivacaine-norepinephrine is an effective new topical anesthetic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113639" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vapocoolants (cold spray) for pain treatment during intravenous cannulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9374583" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Vapocoolant spray is equally effective as EMLA cream in reducing immunization pain in school-aged children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591524" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The effect of vapocoolant spray on pain due to intravenous cannulation in children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032012" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lidocaine iontophoresis versus eutectic mixture of local anesthetics (EMLA) for IV placement in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10092716" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A randomized clinical trial of dermal anesthesia by iontophoresis for peripheral intravenous catheter placement in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9627608" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lidocaine iontophoresis for topical anesthesia before intravenous line placement in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10736141" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparing two methods of topical anesthesia used before intravenous cannulation in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250639" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : EMLA versus TAC for topical anesthesia of extremity wounds in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2748256" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Topical skin anesthesia for venous, subcutaneous drug reservoir and lumbar punctures in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8867250" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Determinants of success and failure of EMLA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8969353" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : EMLA cream as a topical anesthetic before office phlebotomy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487131" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Toxicity of local anesthetics in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042548" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12359791" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Topical anesthetics for intravenous insertion in children: a randomized equivalency study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15601345" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized, double-blind comparison study of EMLA and ELA-Max for topical anesthesia in children undergoing intravenous insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15777110" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A critical review of the topical local anesthetic amethocaine (Ametop) for pediatric pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546268" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Amethocaine versus EMLA for successful intravenous cannulation in a children's emergency department: a randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856039" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : EMLA and amethocaine for reduction of children's pain associated with needle insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28130888" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : First-time success with needle procedures was higher with a warm lidocaine and tetracaine patch than an eutectic mixture of lidocaine and prilocaine cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280850" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A novel needle-free powder lidocaine delivery system for rapid local analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450903" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Needle-free powder lidocaine delivery system provides rapid effective analgesia for venipuncture or cannulation pain in children: randomized, double-blind Comparison of Venipuncture and Venous Cannulation Pain After Fast-Onset Needle-Free Powder Lidocaine or Placebo Treatment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428534" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A comparison of a needle-free injection system for local anesthesia versus EMLA for intravenous catheter insertion in the pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645542" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Jet Injection of 1% buffered lidocaine versus topical ELA-Max for anesthesia before peripheral intravenous catheterization in children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19388923" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A randomized, double-blind controlled study of jet lidocaine compared to jet placebo for pain relief in children undergoing needle insertion in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520120" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Relief of pain and anxiety in pediatric patients in emergency medical systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23109683" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Relief of pain and anxiety in pediatric patients in emergency medical systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978010" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : On the front lines: lessons learned in implementing multidisciplinary peripheral venous access pain-management programs in pediatric hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29486590" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacological interventions for reducing pain related to immunization or intramuscular injection in children: A mixed treatment comparison network meta-analysis of randomized controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629683" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The "ouchless emergency department". Getting closer: advances in decreasing distress during painful procedures in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2664722" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : TAC: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7838644" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lidocaine adrenaline tetracaine gel versus tetracaine adrenaline cocaine gel for topical anesthesia in linear scalp and facial lacerations in children aged 5 to 17 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7832348" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tetracaine, epinephrine (adrenalin), and cocaine (TAC) versus lidocaine, epinephrine, and tetracaine (LET) for anesthesia of lacerations in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9832666" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Topical anesthesia for pediatric lacerations: a randomized trial of lidocaine-epinephrine-tetracaine solution versus gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917323" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pretreatment of lacerations with lidocaine, epinephrine, and tetracaine at triage: a randomized double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229943" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : LET versus EMLA for pretreating lacerations: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12436830" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effective topical anesthetic agents and techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110919" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of Topical Anesthesia on Pain from Needle Insertion and Injection and Its Relationship with Anxiety in Patients Awaiting Apical Surgery: A Randomized Double-blind Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27595728" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of Topical Anesthesia with Lidocaine-prilocaine (EMLA) Cream and Local Pressure on Pain during Infiltration Injection for Maxillary Canines: A Randomized Double-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412890" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Topical anaesthetic or vasoconstrictor preparations for flexible fibre-optic nasal pharyngoscopy and laryngoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192668" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of topical anesthetics and vasoconstrictors vs lubricants prior to nasogastric intubation: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20825806" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lidocaine gel as an anesthetic protocol for nasogastric tube insertion in the ED.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20678892" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Reducing the pain of nasogastric tube intubation with nebulized and atomized lidocaine: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28917955" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lidocaine Gel for Urethral Catheterization in Children: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29232351" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized Clinical Trial of Lidocaine Analgesia for Transurethral Bladder Catheterization Delivered via Blunt Tipped Applicator in Young Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24210368" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Topical lidocaine to improve oral intake in children with painful infectious mouth ulcers: a blinded, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487133" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Eutectic mixture of local anesthetics (EMLA): what is it? What does it do?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9889761" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pediatric dermatologic surgery for the primary care pediatrician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7818623" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Eutectic mixture of local anesthetics (EMLA) cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317421" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Depth and duration of skin analgesia to needle insertion after topical application of EMLA cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12183731" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Methemoglobinemia in an infant receiving nitric oxide after the use of eutectic mixture of local anesthetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9310724" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Signs of methaemoglobinaemia after topical application of EMLA cream in an infant with haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280086" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Are one or two dangerous? Lidocaine and topical anesthetic exposures in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4013630" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Methemoglobinemia associated with a prilocaine-lidocaine cream and trimetoprim-sulphamethoxazole. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10082401" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Histopathology of an adverse reaction to a eutectic mixture of the local anesthetics lidocaine and prilocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967972" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243434" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Topical anesthetics for dermatologic procedures: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129077" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Arrhythmia associated with tetracaine in an extremely low birth weight premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129077" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Arrhythmia associated with tetracaine in an extremely low birth weight premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129077" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Arrhythmia associated with tetracaine in an extremely low birth weight premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25779227" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The use of the needle-free jet injection system with buffered lidocaine device does not change intravenous placement success in children in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198765" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Elevated lidocaine serum concentration after subcutaneous lidocaine administration using a needle-free device in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198765" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Elevated lidocaine serum concentration after subcutaneous lidocaine administration using a needle-free device in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198765" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Elevated lidocaine serum concentration after subcutaneous lidocaine administration using a needle-free device in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8398518" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Dermal anaesthesia: comparison of EMLA cream with iontophoretic local anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897942" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy of pain control with topical lidocaine-epinephrine-tetracaine during laceration repair with tissue adhesive in children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2921260" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Topical lidocaine in the treatment of partial-thickness burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28230244" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Topical anaesthetics for pain control during repair of dermal laceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11498069" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7436066" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Local anesthesia in minor lacerations: topical TAC vs lidocaine infiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1401862" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Toxicity--seizures in an infant caused by (or related to) oral viscous lidocaine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224791" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Methemoglobinemia related to local anesthetics: a summary of 242 episodes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
